Avelumab in G2-3 NET

Official Title

A Phase II Study of Avelumab in Unresectable/Metastatic, Progressive Grade 2-3 Neuroendocrine Tumours


This is a single-centre, single-arm, open-label, phase II trial to evaluate the efficacy and safety of avelumab in subjects with unresectable or metastatic, Grade 2-3, well-differentiated neuroendocrine.tumour.

Trial Description

Primary Outcome:

  • Overall response rate (ORR)
Secondary Outcome:
  • Disease control rate (DCR)
  • Duration of response
  • Progression-free survival (PFS)
  • Overall survival (OS)
  • Rates of treatment-emergent adverse events as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03
  • ORR by irRECIST version 1.1
  • DCR by irRECIST version 1.1
  • Duration of response by irRECIST version 1.1
  • PFS by irRECIST version 1.1
  • OS at 1 year
  • OS at 2 years
  • PFS at 1 year
  • PFS at 2 years

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society